GSE123250
Multi-omics Characterization of WNT Pathway Reactivation to ameliorate BET Inhibitor Resistance in Liver Cancer Cells
The goals of this study are to find drug response genes to different drug combinations in BET inhibitor resistant HepG2 cells. RSEM is taken for consequent data analysis, mapping each sample to the human genome (build hg19) to determine expressions of 57773 transcripts. Overall design: First, HepG2 and Hep3B cells were seeded into 15 cm dish in 2 replicates after treatments with a BET inhibitor (215 nM) or Control (vehicle DMSO) for 24h. Then a series of mRNA profile in HepG2 cells is generated from different inhibitor combination treated samples during 72h by deep sequencing, in duplicate, using Illumina HiSeq 3000. NC represents control, treated with DMSO; 74 means treatments with BET inhibitor at 4000nM; 94 means treatments with CHIR98014 at 4000nM;749 means treatments with BET inhibitor at 4000nM and CHIR98014 at 72nM;794 means treatments with BET inhibitor at 25nM and CHIR98014 at 4000nM.